BridgeBio Pharma, Inc. Restructuring Reserve, Settled without Cash
BridgeBio Pharma, Inc. (BBIO) reported Restructuring Reserve, Settled without Cash of $1.73 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Restructuring and Related Activities
us-gaap:RestructuringReserveSettledWithoutCash2 · last filed 2026-02-24
- BridgeBio Pharma, Inc. restructuring reserve, settled without cash for the quarter ending 2025-12-31 was $970.00K, a 1127.85% increase year-over-year.
- BridgeBio Pharma, Inc. restructuring reserve, settled without cash for the quarter ending 2025-09-30 was $709.00K, a 1629.27% increase year-over-year.
- BridgeBio Pharma, Inc. restructuring reserve, settled without cash for the quarter ending 2025-06-30 was $4.00K, a 91.49% decline year-over-year.
- BridgeBio Pharma, Inc. restructuring reserve, settled without cash for the quarter ending 2025-03-31 was $45.00K, a 83.39% decline year-over-year.
- BridgeBio Pharma, Inc. restructuring reserve, settled without cash for fiscal 2025 was $1.73M, a 294.52% increase from fiscal 2024.
- BridgeBio Pharma, Inc. restructuring reserve, settled without cash for fiscal 2024 was $438.00K.
- BridgeBio Pharma, Inc. restructuring reserve, settled without cash for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- BridgeBio Pharma, Inc. restructuring reserve, settled without cash for fiscal 2022 was $13.89M.
| Period end | Restructuring Reserve, Settled without Cash 3 month | Restructuring Reserve, Settled without Cash 6 month | Restructuring Reserve, Settled without Cash 9 month | Restructuring Reserve, Settled without Cash 12 month |
|---|---|---|---|---|
| 2025-12-31 | $970.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.68M derived: sum of 2 quarters · filed 2026-02-24 | $1.68M derived: sum of 3 quarters · filed 2026-02-24 | $1.73M 10-K · filed 2026-02-24 |
| 2025-09-30 | $709.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $713.00K derived: sum of 2 quarters · filed 2025-10-29 | $758.00K 10-Q · filed 2025-10-29 | $837.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $49.00K 10-Q · filed 2025-08-05 | $128.00K derived: sum of 3 quarters · filed 2026-02-24 | $169.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-03-31 | $45.00K 10-Q · filed 2025-04-29 | $124.00K derived: sum of 2 quarters · filed 2026-02-24 | $165.00K derived: sum of 3 quarters · filed 2026-02-24 | $212.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $120.00K derived: sum of 2 quarters · filed 2026-02-24 | $167.00K derived: sum of 3 quarters · filed 2026-02-24 | $438.00K 10-K · filed 2026-02-24 |
| 2024-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $88.00K derived: sum of 2 quarters · filed 2025-10-29 | $359.00K 10-Q · filed 2025-10-29 | $359.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $318.00K 10-Q · filed 2025-08-05 | $318.00K derived: sum of 3 quarters · filed 2026-02-24 | $318.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $271.00K 10-Q · filed 2025-04-29 | $271.00K derived: sum of 2 quarters · filed 2026-02-24 | $271.00K derived: sum of 3 quarters · filed 2026-02-24 | $271.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $67.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $67.00K derived: sum of 3 quarters · filed 2025-02-20 | $67.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $67.00K derived: sum of 2 quarters · filed 2025-02-20 | $67.00K derived: sum of 3 quarters · filed 2025-02-20 | $13.89M 10-K · filed 2025-02-20 |
| 2022-09-30 | $67.00K 10-Q · filed 2022-11-03 | $67.00K derived: sum of 2 quarters · filed 2023-08-03 | $13.89M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $13.82M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $13.82M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |